Therna Biosciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Therna Biosciences is a private, pre-clinical stage biotech leveraging a proprietary generative AI platform for the design of RNA therapeutics. The company's core innovation is an iterative 'lab-in-the-loop' pipeline that combines computational sequence generation with experimental validation to optimize RNA drugs for expression, silencing, or fine-tuning of genes. Founded by a team with deep expertise in RNA biology and AI, Therna aims to address diseases intractable to traditional modalities and unlock vast commercial potential across multiple therapeutic areas, starting with metabolic and cardiovascular indications. The company is currently pre-revenue and focused on platform development and early pipeline advancement.

MetabolicCardiovascular

Technology Platform

Proprietary generative AI platform integrated with deep RNA biology for the design of custom therapeutic mRNAs and optimal target identification for ASOs/siRNAs. Utilizes an iterative 'lab-in-the-loop' pipeline where AI-generated sequences are experimentally validated and results are used to retrain the AI models.

Opportunities

The massive and growing market for RNA therapeutics, particularly in prevalent chronic conditions like metabolic and cardiovascular diseases, presents a significant commercial opportunity.

Successfully programming desirable properties into RNA drugs could address diseases currently out of reach for traditional modalities, creating first-in-class or best-in-class therapies.

The platform's potential to accelerate and de-risk drug discovery could also make it attractive for strategic partnerships across the biopharma industry.

Risk Factors

Key risks include the unproven nature of the generative AI platform at producing clinical candidates, the intense competition in the RNA therapeutics space from large pharma and well-funded biotechs, and the persistent biological challenges of delivery, durability, and safety for RNA drugs.

As a pre-revenue company, Therna is also highly dependent on securing future financing to advance its pipeline.

Competitive Landscape

Therna operates in the highly competitive RNA therapeutics arena, competing against established giants like Alnylam (siRNA), Ionis (ASO), Moderna, and BioNTech (mRNA), as well as numerous startups leveraging computational approaches. Differentiation hinges on the unique integration of its generative AI with deep RNA biology and its closed-loop 'lab-in-the-loop' validation system, aiming for superior speed and precision in designing programmable RNA medicines.

More companies in Biologics / Biosimilars →More companies in United States →